Latest Comments

Pipeline biosimilar surge in emerging markets

Pipeline biosimilar surge in emerging markets

Can DAA treatment increase the risk of HCC? Emerging data points towards ‘no’

Can DAA treatment increase the risk of HCC? Emerging data points towards ‘no’

How your gut microbiome can interfere with cancer treatment and how to avoid it

How your gut microbiome can interfere with cancer treatment and how to avoid it

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Highlights from the 2017 ATS Conference: positive results for AstraZeneca’s Daliresp beyond reducing the risk of exacerbations

Eiger Bio’s PAH drug Ubenimex moves one step closer to fulfilling an unmet need

Eiger Bio’s PAH drug Ubenimex moves one step closer to fulfilling an unmet need

Lundbeck and Otsuka's brexipiprazole shows positive but confusing results

Lundbeck and Otsuka's brexipiprazole shows positive but confusing results

Hepatitis C Therapy – A Light at the End of the Tunnel?

Hepatitis C Therapy – A Light at the End of the Tunnel?

FMT National Registry Will Help Elucidate Best Practices for Recurrent C. difficile Infections

FMT National Registry Will Help Elucidate Best Practices for Recurrent C. difficile Infections

China, US, and Brazil Face Rise in HIV-HCV Co-infection

China, US, and Brazil Face Rise in HIV-HCV Co-infection

FDA’s acceptance of Santen’s Opsiria marks a milestone for the company

FDA’s acceptance of Santen’s Opsiria marks a milestone for the company

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

PCR-based C. difficile Cytotoxin assays alone not appropriate for pivotal endpoint measures

PCR-based C. difficile Cytotoxin assays alone not appropriate for pivotal endpoint measures

China’s pharma market transformation to fuel global industry growth

China’s pharma market transformation to fuel global industry growth

Newest class of type 2 diabetes drugs continues its push into the US market

Newest class of type 2 diabetes drugs continues its push into the US market

Pharma price hiking: why does it happen?

Pharma price hiking: why does it happen?

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Targeting of specific patient groups to break into the epilepsy market

Targeting of specific patient groups to break into the epilepsy market

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

Inclisiran: a novel approach to targeting cholesterol and patient needs

Inclisiran: a novel approach to targeting cholesterol and patient needs

Will improved breast cancer testing result in better access to HER2-Positive therapy?

Will improved breast cancer testing result in better access to HER2-Positive therapy?

Win for AstraZeneca as Symbicort gains six months of pediatric exclusivity in the US

Win for AstraZeneca as Symbicort gains six months of pediatric exclusivity in the US